The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,868.00
Bid: 1,854.00
Ask: 1,860.00
Change: 0.00 (0.00%)
Spread: 6.00 (0.324%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,868.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM and IMS

11 Nov 2010 07:00

RNS Number : 9786V
Genus PLC
11 November 2010
 



For Immediate Release 11 November 2010

 

 

 

GENUS plc

("Genus" or "the Company")

 

AGM and Interim Management Statement

 

At the Annual General Meeting of Genus to be held today at 2.30pm, the following interim management statement will be made:

 

Markets

 

The extent of the market recovery seen in most markets in the second half of our last financial year has been sustained.

 

The recent increase in animal feed costs has eroded short term profitability for many pig producers. Whilst some producers have become more cautious, the outlook for USA pig prices remains firm and most producers should continue to be profitable throughout 2011. Therefore, we expect the general improvement in demand that Genus has experienced in the first four months of the current financial year to continue.

 

In the bovine sector, milk prices continued to be at acceptable levels in most markets and showed a modest improvement in the USA.

 

Trading Performance

 

Adjusted profit before tax* for the four months to 31 October 2010 was in line with the Board's expectations and well ahead of the same period last year, reflecting a continuation of the trend of improved performance reported for the second half of the last financial year.

Revenue for the four months to 31 October 2010 rose strongly. Porcine sales of breeding animals were significantly higher as customers returned to updating their genetics, particularly in the USA, and bovine volumes also increased.

 

Adjusted operating profit* for the four months continued to grow. With improving global markets, profits rose strongly in both North and South America, particularly in the porcine sector. Cost reductions implemented in our USA dairy operations, together with slightly higher average selling prices, led to an improvement in bovine profits in a stable market. Profits in Europe were lower than in the same period last year due to the phasing of bovine sales in certain distributor markets. In the Far East, bovine prices in Australia improved as that market recovered and semen sales volumes in China increased. However, profits in the region were held back by poor performance by the porcine business in China where pig prices remained depressed.

 

Interest costs were lower, as a result of lower net debt and reduced pension interest costs.

 

Trends in trading performance have not been materially affected by exchange rate movements.

 

Strategic Progress

 

Good strategic progress was made in China. A Government licence has been received allowing the operation of the recently completed bovine stud and sales of locally produced semen have commenced.

 

In India, the recently announced 5 year commercial agreement with Chitale Dairy will provide local bull stud facilities for Genus sires in this large and fast growing dairy market. Sales of locally produced semen have already begun.

We are also pleased to announce the acquisition of a Genus bovine production facility in Krasnodar, Russia. The acquired facilities will be used to establish local production to supplement sales of imported semen in Russia with sales expected to begin towards the end of the second half of the current financial year.

 

Financial Position

 

Net debt at the end of October was £79.7m. This was significantly lower than at the same time last year (£95.2m) reflecting the positive underlying cash generation within the business now that the major expansion of production facilities has been completed.

 

Outlook

 

We have made an encouraging start to the current financial year. Despite higher feed costs, we expect to continue to make good progress in the year ahead and fully to meet the Board's expectations for the year. The strategic initiatives reported above are expected to add to growth in the next financial year.

 

*Adjusted profit before tax and adjusted operating profit are calculated before net IAS41 valuation movements in biological assets, amortisation of acquired intangibles, share based payments, exceptional items and other gains and losses. The Board believes these additional non-GAAP measures provide a useful alternative measure for shareholders of the trading performance of the Group.

 

 

For further information please contact:

 

Genus plc Tel: 01256 345970

 

Richard Wood, Chief Executive

John Worby, Finance Director

 

Buchanan Communications Tel: 0207 466 5000

 

Charles Ryland

Suzanne Brocks

 

This announcement is available on the Genus website, www.genusplc.com

 

 

 

 

About Genus:

 

Genus plays a key role in the world's agricultural economy in its creation of advances in animal breeding through naturally applied biotechnology, helping farmers and food producers across the world to improve quality and increase output.

 

Genus provides superior natural animal genetics, enabling our global customers in the bovine and porcine supply chain to produce offspring in their herds with greater production efficiency, milk and meat output and quality. The challenge of meeting growing global demand for milk, pork and beef from the decreasing resources available for food production requires innovative solutions that Genus provides.

 

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production.

 

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals and the biotechnology used to improve them. Genus' global production and distribution network underpins our unique position in the world's growing agricultural markets.

 

Headquartered in Basingstoke, England, Genus is a FTSE250 company that operates in 30 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBLBDBLBBBGGG
Date   Source Headline
1st May 20241:59 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSInterim Results
15th Feb 20247:00 amRNSTrading Update
1st Feb 20244:24 pmRNSBlock listing Interim Review
1st Feb 20244:21 pmRNSTotal Voting Rights
12th Dec 20237:00 amRNSNon-Executive Director Appointment
22nd Nov 20231:08 pmRNSResult of AGM
22nd Nov 20237:00 amRNSAGM Trading Update
1st Nov 20234:46 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSCapital Markets Event
13th Oct 20237:00 amRNSAnnual Report and Annual General Meeting
5th Oct 202310:19 amRNSPos. determination-PRRS resistant pigs-Colombia
2nd Oct 202311:12 amRNSTotal Voting Rights
15th Sep 20231:07 pmRNSDirector/PDMR Shareholding
15th Sep 202310:04 amRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSPreliminary Results
25th Aug 20238:35 amRNSNotification of Major Holdings
23rd Aug 20239:25 amRNSDirectorate Change
1st Aug 202311:41 amRNSBlock listing Interim Review
1st Aug 202311:36 amRNSTotal Voting Rights
3rd Jul 202311:02 amRNSTotal Voting Rights
16th Jun 20235:33 pmRNSNational Milk Records plc - Form 8.3
16th Jun 20235:10 pmRNSForm 8.3 (OPD) - National Milk Records plc
8th Jun 20233:51 pmRNSDirector/PDMR Shareholding
7th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20235:08 pmRNSNotification of Major Holdings
5th Jun 20239:12 amRNSAdditional Listing
24th May 20234:54 pmRNSNotification of Major Holdings
18th May 20231:32 pmRNSDirector/PDMR Shareholding
16th May 20236:16 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSTrading Update
9th May 20234:30 pmRNSNotification of Major Holdings
3rd May 20238:44 amRNSTotal Voting Rights
2nd May 20237:00 amRNSShare Award for Incoming CEO
3rd Apr 202311:27 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSAppointment of Chief Executive Officer Designate
21st Mar 20232:58 pmRNSApplication for Block Listing
6th Mar 202312:53 pmRNSNotification of Major Holdings
2nd Mar 20231:51 pmRNSNotification of Major Holdings
1st Mar 20232:20 pmRNSNotification of Major Holdings
24th Feb 20235:13 pmRNSDirector/PDMR Shareholding
24th Feb 202311:39 amRNSNotification of Major Holdings
23rd Feb 20239:33 amRNSReplacement: Interim Results
23rd Feb 20237:00 amRNSChief Executive Officer Retirement
23rd Feb 20237:00 amRNSInterim Results
21st Feb 20235:03 pmRNSNotification of Major Holdings
10th Feb 20232:08 pmRNSNotification of Major Holdings
1st Feb 202310:00 amRNSBlock listing Interim Review
23rd Nov 20221:02 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.